The AbDrop™ platform uses microfluidic technology to encapsulate individual plasma cells in droplets. This high-throughput approach enables researchers to screen millions of plasma B cells in a single day.
Workflow Highlights:
One Day: Millions of B cells screened for antibody-producing potential.
One Week: High-throughput sequencing and data analysis.
One Month: Purified antibodies with validated activity.
One Screening Cycle: Hundreds of naturally paired heavy and light chains obtained.
This platform reduces reagent consumption, integrates multiple development steps, and increases precision. Researchers can identify unique and functional antibodies faster, ensuring the discovery of effective therapeutic candidates.
Cyagen’s HUGO-Ab™ Mice: Cutting-Edge Human Antibody Models
The HUGO-Ab™ mice are genetically engineered to produce fully human antibodies. Using proprietary TurboKnockout® ES technology, these mice achieve stable phenotypic and functional outcomes without requiring humanization steps. Advantages of HUGO-Ab™ Mice:
High Affinity and Low Immunogenicity: Antibodies derived from these mice exhibit strong target binding and minimal immune response, critical for safety and efficacy.
Proven Performance: Recognized by leading institutions, HUGO-Ab™ mice have consistently delivered high-quality therapeutic antibodies.
Enhanced Diversity: These mice include the full spectrum of human antibody heavy and light chain genes, increasing the diversity of potential antibody candidates.
Our High-throughput Fully Human Antibody Discovery Platform integrates Cyagen’s HUGO-Ab™ mice with Biointron’s AbDrop™ microdroplet-based single B cell screening. This powerful combination accelerates the discovery and development of fully human antibodies, reducing the time from target identification to therapeutic candidate to just three months. Learn more about the service here.
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
